American College of Clinical Pharmacy
      Search      Cart
         

HIV PRN and Women's Health PRN Focus Session -- HIV and Gender: Implications for Prevention and Care

Sunday, October 08, 2017 from 2:15 PM to 3:45 PM MST at Phoenix Convention Center North Building Street Level: Meeting Room 128

Available for 1.50 hours of CPE credit
Activity Number: 0217-0000-17-141-L02-P
Activity Type: A Knowledge-Based Activity


Speakers
  • Kimberly  Scarsi, Pharm.D., M.Sc.Moderator: Kimberly Scarsi, Pharm.D., M.Sc.
    Associate Professor, University of Nebraska Medical Center, College of Pharmacy, Omaha, Nebraska
      View Biography

An Ounce of PrEP-vention: Preventing HIV in Women
2:15 PM

Speakers
  • Mackenzie L. Cottrell, Pharm.D.Speaker: Mackenzie L. Cottrell, Pharm.D.
    Research Assistant Professor, College of Pharmacy, University of North Carolina, Chapel Hill, North Carolina


Learning Objectives
1. Recognize gender disparities in the uptake of pre-exposure prophylaxis (PrEP).
2. Describe novel PrEP strategies for women.
3. Compare and contrast HIV prevention strategies in men versus women.
My Preferred Pronoun Is … Optimizing Care for Transgender Women
2:45 PM

Speakers
  • Joshua  Havens, Pharm.D.Speaker: Joshua Havens, Pharm.D.
    Specialty Care Clinic, Nebraska Medicine, University of Nebraska Medical Center, Omaha, Nebraska
      View Biography


Learning Objectives
1. Recommend common medication therapies for gender affirming therapy.
2. Interpret goals of therapy and monitoring parameters for hormonal pharmacotherapy.
3. Describe possible drug-drug interactions between gender affirming therapy and antiretrovirals used for HIV treatment or prevention.
The Changing Tide: Considerations Throughout the Life Span of Women Living with HIV
3:15 PM

Speakers
  • Jennifer Cocohoba, Pharm.D.Speaker: Jennifer Cocohoba, Pharm.D.
    Professor of Clinical Pharmacy, University of California, San Francisco, San Francisco, California
      View Biography


Learning Objectives
1. Compare and contrast the clinical outcomes and unique risks of antiretroviral pharmacotherapy in women versus men.
2. Manage drug-drug interactions between hormone replacement therapy or contraceptives and antiretrovirals.
3. Choose an optimal antiretroviral therapy regimen for an HIV-infected pregnant woman.